Other Deal Trends 2026: Activity Up 1271% in 6 Months

96 deals in six months — up from 7 in the prior half-year. That's a +1271% surge in deal activity across the 'other' modality category between the periods ending February 2026 and August 2026. This isn't statistical noise. It reflects a structural shift: Big Pharma BD teams are aggressively licensing and acquiring assets that don't fit neatly into antibody, small molecule, cell therapy, or gene therapy buckets — and the capital deployed confirms conviction, not experimentation.

The Data — Other Deal Activity, Period over Period

A jump from single digits to nearly triple digits in one period demands scrutiny. This isn't a gradual uptick driven by a few outliers. The breadth of the increase — from 7 to 96 — suggests multiple concurrent forces converging. Seven deals in six months was a trickle, barely registering against the thousands of biopharma transactions tracked annually. Ninety-six represents a category that has arrived.

What's Driving the Trend

Pipeline desperation meets modality diversification. The traditional modality lanes — monoclonal antibodies, ADCs, small molecules — are crowded. Pharma BD teams chasing differentiated mechanisms are forced to look at modalities that historically sat outside core comfort zones: protein degraders beyond PROTACs, engineered peptides, radiopharmaceuticals, microbiome therapeutics, and novel complement-targeting approaches. The Omeros–Novo Nordisk deal for a complement-targeted MASP-2 inhibitor at $2.4B total deal value is the clearest proof point. Novo didn't license that asset because it fit a traditional bucket. They licensed it because complement inhibition in obesity-adjacent metabolic pathways is differentiated enough to justify a premium.

Regulatory tailwinds are real, but secondary. FDA's increasing comfort with accelerated approvals for novel mechanism-of-action therapies has lowered perceived regulatory risk for assets that previously looked exotic. But the primary driver is strategic: the patent cliff math doesn't work if you're only buying into established modality classes where every Big Pharma competitor is already bidding. The economics of other licensing 2026 reflect this scarcity premium — assets that defy easy categorization command attention precisely because they offer pipeline differentiation that antibody #47 in a given target class cannot.

Capital availability is enabling speed. With pharma balance sheets still flush — Amgen, AstraZeneca, Novartis, and Novo Nordisk collectively holding over $80B in deployable capital — the constraint isn't money. It's finding assets worth buying. The 'other' category has become a release valve for BD teams under pressure to deploy. When traditional categories are picked over, you expand your aperture. That's exactly what the data shows. Check our Deal Benchmarks page for how these deal structures compare to ADC and antibody transactions in the same period.

Notable Deals

The CSPC–AstraZeneca deal is the headliner and deserves the most attention. A $1.2B upfront with $18.5B in total deal value is not a licensing deal — it's a conviction trade. AstraZeneca is signaling that whatever CSPC has in its pipeline (likely a novel oncology platform that doesn't slot into conventional categories) is worth more than most entire biotech companies. The upfront-to-TDV ratio of roughly 6.5% is aggressive by any standard, suggesting heavy milestone loading, but $1.2B in upfront cash is enough to fund CSPC's pipeline for years. This deal alone would make other licensing 2026 a landmark period.

The Omeros–Novo Nordisk transaction at $2.4B TDV validates complement inhibition as a platform play, not a niche bet. Novo's interest likely extends beyond the lead asset into the broader MASP-2 biology. BridgeBio's $105M upfront from Novartis is notable as the smallest deal on this list but represents a clean validation event for a biotech that has historically struggled with market perception. Amgen–BeiGene, with terms undisclosed, is harder to evaluate but the pairing itself — a US large-cap with a China-rooted oncology powerhouse — suggests cross-border platform access.

Collectively, these five deals closed within a six-day window in July 2026. That concentration isn't coincidental. It suggests competitive dynamics where multiple pharma BD teams were racing to close before competitors could lock up remaining differentiated assets.

What This Means for BD Teams Right Now

If you're selling: This is unambiguously a seller's market for assets in non-traditional modality categories. The scarcity premium is real and quantifiable — $18.5B TDV for a single asset from a Chinese pharma company would have been unthinkable 18 months ago. If your platform doesn't fit neatly into a modality box, lean into that as a strength, not a liability. BD teams at large pharma are explicitly tasked with finding differentiated mechanisms, and your unconventional profile is your leverage.

If you're buying: Move fast. The data shows acceleration, not stabilization. Waiting for 'better terms' in a category experiencing +1271% deal volume growth is a losing strategy. The best assets in this category will be gone within 12 months. Structure deals with higher upfronts to win competitive processes — licensors in this market have options, and a creative milestone structure won't beat a larger cash commitment from a competitor. Use Solidus to model upfront-to-TDV ratios against the current cohort before entering term sheet discussions.

Deal structure shifts: We're seeing a clear trend toward larger upfronts as a percentage of TDV in competitive situations. The BridgeBio–Novartis deal's $105M upfront, while modest relative to the CSPC mega-deal, represents a meaningful cash commitment for a platform-stage asset. Equity components and co-development structures are gaining favor as licensors push for more value capture beyond traditional royalty stacks. Options deals — where the buyer locks in rights to license upon data readout — are also proliferating in this category because they let pharma derisk novel mechanisms while maintaining competitive positioning.

Benchmark your deal against current market rates using the Ambrosia calculator. With 96 transactions now in the dataset for this period, the benchmarks are statistically meaningful for the first time. Whether you're negotiating upfronts, milestone schedules, or royalty tiers, the data exists to anchor your terms in market reality rather than precedent from 2023.